Friday 6 November 2026 Export LNTH’s income statement to Excel — free account

Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue: +1.54%
EPS: −17.1%
Free cash flow: +7.71%
Total debt: +0.52%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

100.74 0.04 +0.04%

Follow LNTH

Alert me

Market cap: $6.6B
P/E: 24.3×
Fwd P/E: 21.3×
Dividend yield: —
F-score: 5/9
Altman Z: 4.25
Beneish M: −2.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Lantheus Holdings, Inc. (LNTH) revenue by segment, product and region

	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022
Product revenue, net	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
License and royalty revenues	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Nuclear	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Rebates And Allowances	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Xenon	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
PYLARIFY	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
DEFINITY	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TechneLite	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Strategic partnerships and other revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other precision diagnostics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other radiopharmaceutical oncology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Neuraceq	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Total oncology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Total precision diagnostics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Lantheus Holdings, Inc. (LNTH) revenue by segment, product and region

Stockrow Weekly